Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery

Background: Renal cell cancer (RCC) is one of the 10 most common cancers in the world, and its incidence is increasing, whereas mortality is declining only in developed countries. Therefore, two collaborative groups, The Latin American Oncology Cooperative Group-Genitourinary Section (LACOG-GU) and the Latin American Renal Cancer Group (LARCG), held a consensus meeting to develop this guideline. Methods: Issues (134) related to the treatment of RCC were previously formulated by a panel of experts. The voting panel comprised 26 specialists (urologists and medical oncologists) from the LACOG-GU/LARCG. A consensus was reached if 75% agreement was achieved. If there was less concordance, a new discussion was undertaken, and a consensus was determined by the most votes after a second voting session. Results: The expert meeting provided recommendations that were in line with the global literature; 75.0% of the recommendations made by the panel of experts were evidence-based level A, 22.5% of the recommendations were level B, and 2.5% of the recommendations were level D. Conclusions: This review suggests recommendations for the surgical treatment of RCC according to the LACOG-GU/LARCG experts.

[1]  A. Jemal,et al.  Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. , 2019, The Lancet. Public health.

[2]  F. Bray,et al.  Epidemiology of Renal Cell Carcinoma. , 2019, European urology.

[3]  M. Casey,et al.  Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[5]  Inderbir S. Gill,et al.  Impact of Surgical Factors on Robotic Partial Nephrectomy Outcomes: Comprehensive Systematic Review and Meta‐Analysis , 2018, The Journal of urology.

[6]  R. Uzzo,et al.  Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and >5-yr Clinical Outcomes. , 2018, European urology.

[7]  Coral L. Atoria,et al.  Percutaneous Ablation Versus Partial and Radical Nephrectomy for T1a Renal Cancer , 2018, Annals of Internal Medicine.

[8]  I. Kaplan,et al.  Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK) , 2018, Cancer.

[9]  R. Carlini,et al.  Determinant factors for chronic kidney disease after partial nephrectomy , 2018, Oncoscience.

[10]  J. Prada,et al.  Epidemiology of renal cancer in developing countries: Review of the literature. , 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[11]  S. Wong,et al.  Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries , 2017, Scientific Reports.

[12]  K. Fareed,et al.  Management of the small renal mass , 2017, Translational andrology and urology.

[13]  R. Motzer,et al.  Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Jeffrey A. Cadeddu,et al.  Adult Urology Oncology : Adrenal / Renal / Upper Tract / Bladder lized Renal Cancer : AUA Guideline , 2017 .

[15]  E. Bass,et al.  Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[16]  A. Belldegrun,et al.  Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial , 2017, JAMA oncology.

[17]  J. Patard,et al.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. , 2016, The New England journal of medicine.

[18]  B. Leibovich,et al.  Renal Mass Biopsy: Always, Sometimes, or Never? , 2016, European urology.

[19]  K. Bensalah,et al.  Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. , 2016, European urology.

[20]  D. Parekh,et al.  Current Paradigm for Ischemia in Kidney Surgery. , 2016, The Journal of urology.

[21]  J. Manola,et al.  Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial , 2016, The Lancet.

[22]  C. Stief,et al.  Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[23]  E. Bass,et al.  Diagnostic Accuracy and Risks of Biopsy in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma: Systematic Review of the Literature. , 2016, The Journal of urology.

[24]  E. Bass,et al.  Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis. , 2016, The Journal of urology.

[25]  Mark W. Ball,et al.  Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. , 2015, European urology.

[26]  H. Kang,et al.  Diagnostic approach to hereditary renal cell carcinoma. , 2015, AJR. American journal of roentgenology.

[27]  Ariana Znaor,et al.  International variations and trends in renal cell carcinoma incidence and mortality. , 2015, European urology.

[28]  M. Carini,et al.  Simple enucleation versus standard partial nephrectomy for clinical T1 renal masses: perioperative outcomes based on a matched-pair comparison of 396 patients (RECORd project). , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[29]  L. Qu,et al.  Robotic versus Open Partial Nephrectomy: A Systematic Review and Meta-Analysis , 2014, PloS one.

[30]  W. Gregory,et al.  Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours , 2013, BJU international.

[31]  J. Milner,et al.  Renal lymph nodes for tumor staging: appraisal of 871 nephrectomies with examination of hilar fat. , 2013, Archives of pathology & laboratory medicine.

[32]  Paul Russo,et al.  New Chronic Kidney Disease and Overall Survival After Nephrectomy for Small Renal Cortical Tumors. , 2013, Urology.

[33]  P. Verze,et al.  Long-term oncological and functional results of extraperitoneal laparoscopic radical prostatectomy: one surgical team’s experience on 1,600 consecutive cases , 2013, World Journal of Urology.

[34]  M. Lapitan,et al.  Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. , 2012, European urology.

[35]  F. Montorsi,et al.  A review of integrated staging systems for renal cell carcinoma. , 2012, European urology.

[36]  R. El Dib,et al.  Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta‐analysis of case series studies , 2012, BJU international.

[37]  R. Uzzo,et al.  Small renal masses progressing to metastases under active surveillance , 2012, Cancer.

[38]  Lara K. Suh,et al.  Tumour diameter and decreased preoperative estimated glomerular filtration rate are independently correlated in patients with renal cell carcinoma , 2012, BJU international.

[39]  J. Patard,et al.  Lymph node dissection in renal cell carcinoma. , 2011, European urology.

[40]  U. Boggi,et al.  Renal cell carcinoma with caval involvement: contemporary strategies of surgical treatment. , 2011, Urologic oncology.

[41]  J. Nakashima,et al.  Impact of tumor size on renal function and prediction of renal insufficiency after radical nephrectomy in patients with renal cell carcinoma. , 2011, The Journal of urology.

[42]  Joseph O. Deasy,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .

[43]  L. Klotz,et al.  Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. , 2011, European urology.

[44]  M. Carini,et al.  Simple enucleation is equivalent to traditional partial nephrectomy for renal cell carcinoma: results of a nonrandomized, retrospective, comparative study. , 2011, The Journal of urology.

[45]  M. Meng,et al.  Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. , 2011, The Journal of urology.

[46]  Wong-Ho Chow,et al.  Epidemiology and risk factors for kidney cancer , 2010, Nature Reviews Urology.

[47]  M. Stifelman,et al.  Robot assisted partial nephrectomy versus laparoscopic partial nephrectomy for renal tumors: a multi-institutional analysis of perioperative outcomes. , 2009, The Journal of urology.

[48]  Sam S. Chang,et al.  Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Data Base , 2009, Cancer.

[49]  I. Gill,et al.  Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. , 2009, The Journal of urology.

[50]  G. Haber,et al.  Seven years after laparoscopic radical nephrectomy: oncologic and renal functional outcomes. , 2008, Urology.

[51]  R. Uzzo,et al.  Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. , 2008, The Journal of urology.

[52]  E. Wallen,et al.  Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention. , 2007, The Journal of urology.

[53]  M. Carini,et al.  Simple enucleation for the treatment of PT1a renal cell carcinoma: our 20-year experience. , 2006, European urology.

[54]  Andrew J Vickers,et al.  Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. , 2006, The Lancet. Oncology.

[55]  A. Hanlon,et al.  The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. , 2006, The Journal of urology.

[56]  U. Jonas,et al.  The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. , 2005, European urology.

[57]  C. Wood,et al.  Evaluation of the intact specimen after laparoscopic radical nephrectomy for clinically localized renal cell carcinoma identifies a subset of patients at increased risk for recurrence. , 2005, The Journal of urology.

[58]  M. Gotoh,et al.  Laparoscopic radical nephrectomy for renal cell carcinoma: the standard of care already? , 2005, Current opinion in urology.

[59]  J. Patard,et al.  Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Cheville,et al.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. , 2002, The Journal of urology.

[61]  S. M. Suarez,et al.  Cavoatrial tumor thrombus: single-stage surgical approach with profound hypothermia and circulatory arrest, including a review of the literature. , 2002, The Journal of thoracic and cardiovascular surgery.

[62]  Y. Okita,et al.  Renal cell carcinoma with extension of tumor thrombus into the vena cava: surgical strategy and prognosis. , 2001, Journal of vascular surgery.

[63]  J. Benichou,et al.  Population attributable risk of renal cell cancer in Minnesota. , 1998, American journal of epidemiology.

[64]  B. Reichart,et al.  Resection of hypernephromas with vena caval or right atrial tumor extension using extracorporeal circulation and deep hypothermic circulatory arrest: a multidisciplinary approach. , 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[65]  J. Richie,et al.  Aggressive surgical approach to renal cell carcinoma: review of 130 cases. , 1979, The Journal of urology.

[66]  L. Soutter,et al.  The value of the thoracoabdominal incision in the removal of kidney tumors. , 1949, The New England journal of medicine.

[67]  R. Sylvester,et al.  A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. , 2011, European urology.

[68]  J. Cheville,et al.  Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. , 2011, European urology.

[69]  A. Shalhav,et al.  Chronic kidney disease before and after partial nephrectomy. , 2011, The Journal of urology.

[70]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[71]  C. J. Robson.  Radical nephrectomy for renal cell carcinoma. , 1963, The Journal of urology.